Navigation Links
Boehringer Ingelheim Pharmaceuticals, Inc. Receives the NCQA 'Seal Of Approval'
Date:2/19/2008

RIDGEFIELD, Conn., Feb. 19 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that it has received the prestigious certification from the National Committee for Quality Assurance (NCQA) for its educational resources and programs related to chronic obstructive pulmonary disease (COPD). A chronic illness that may result in severe morbidity, COPD, which includes chronic bronchitis, emphysema, or both, is the fourth-leading cause of death in the United States. (1)

To address this problem and inform the public about COPD, Boehringer Ingelheim has and continues to raise awareness about this serious disease through education and initiatives for patients, healthcare practitioners, and health plans. As a result of these efforts, the company has become one of just a few recognized by the NCQA for their efforts.

"This recognition is an important milestone that highlights our commitment to making a difference in the management of chronic diseases," said Chris Barrett, Senior Vice President, Managed Markets. "Boehringer Ingelheim is dedicated to helping to improve the lives of people living with serious chronic diseases such as COPD, and we continue to collaborate with the NCQA as we develop health management programs in other important areas, such as stroke and prevention of secondary stroke."

Margaret E. O'Kane, President of NCQA agrees. "Earning NCQA Disease Management Certification indicates that a disease management (DM) program excels in the specific area in which it was reviewed, either program design, patient outreach, or DM systems. It's an accomplishment of which to be very proud."

About Boehringer Ingelheim

Boehringer Ingelheim Pharmaceuticals, Inc., based in Ridgefield, CT, is the largest U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies. The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 137 affiliates in 47 countries and approximately 38,400 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel products of high therapeutic value for human and veterinary medicine.
For more information, please visit http://us.boehringer-ingelheim.com.

(1.) National Heart, Lung, and Blood Institute. Morbidity & Mortality:

2007 chart book on cardiovascular, lung, and blood diseases.

[NHLBI2007/P9/Chart 2-8] June 2007. U.S. Department of Health and

Human Services, National Institutes of Health; 2007.

http://www.nhlbi.nih.gov/resources/docs/cht-book.htm. Accessed December 12,

2007.


'/>"/>
SOURCE Boehringer Ingelheim Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Boehringer Ingelheim Receives Top Honor as Worlds Most Respected Biopharmaceutical Employer in Science 2007 Top Employers Survey
2. Dalton Medicinal Chemistry Partners Achieves Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
3. Astellas and Boehringer Ingelheim Reach Settlement Agreement with Ranbaxy on Flomax Patent Case
4. Dalton Medicinal Chemistry Partners Achieves Another Milestone in Collaboration with Boehringer Ingelheim (Canada) Ltd.
5. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)
6. Prestwick Pharmaceuticals, Inc. Continues to Build Management Team With Appointment of Martin Stogniew, Ph.D. as Executive Vice President, Chief Technology Officer
7. Keryx Biopharmaceuticals, Inc. Announces Appointment of Michael P. Tarnok to Board of Directors
8. Keryx Biopharmaceuticals, Inc. Announces Conference Call to Discuss Strategic Alliance
9. Keryx Biopharmaceuticals, Inc. Enters into Licensing Agreement with Japan Tobacco and Torii Pharmaceutical for Development and Commercialization of Hyperphosphatemia Drug in Japan
10. NPS Pharmaceuticals, Inc. Announces an Increase in Tender Offer Price for Its 3.0% Convertible Notes Due 2008 and Extends Expiration Date Until October 17, 2007
11. Alseres Pharmaceuticals, Inc. to Present at Bio Investor Forum 2007 Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)...  GlobeImmune, Inc. today announced it has entered into ... shares of its common stock to NantCell, Inc., a ... the sale of its common stock, NantCell has agreed ... GlobeImmune 200,000 shares, an estimated $2.0 million in value, ... pleased to enter into this strategic agreement with NantCell," ...
(Date:3/23/2017)... 2017 NetworkNewsWire Editorial Coverage  ... Cancer remains one ... on health care systems, in terms of costs and resources. ... does the development of innovative and efficient therapies that demonstrate ... many types of cancer treatments, a growing number of patients ...
(Date:3/23/2017)... ... March 23, 2017 , ... ... announced the hire of Dr. Sigmund “Sig” Floyd as Vice President ? Global ... and joint development activities. , “Dr. Floyd’s career has spanned 30 years in ...
(Date:3/22/2017)... 22, 2017  UBM and the Massachusetts Medical ... extended partnership and the third annual Massachusetts Medtech Week. ... 21 st Annual MassMEDIC Conference held in ... 3-4, 2017. MassMEDIC will feature ... President and CEO, Scott Whitaker , at ...
Breaking Biology Technology:
(Date:3/2/2017)... , March 2, 2017 Summary ... to better understand Merck KGaA and its partnering interests ... https://www.reportbuyer.com/product/3605601/ Description The Partnering Deals and ... the partnering activity of one of the world,s leading ... are prepared upon purchase to ensure inclusion of the ...
(Date:2/28/2017)... ANGELES , Feb. 28, 2017   Acuant ... verification software globally, announces significant enhancements to new and ... May 2016. New products include mobile and desktop Acuant ... DocX TM - a real time manual review ... core idScan® technology provides the fastest and most accurate ...
(Date:2/26/2017)... , Feb. 25, 2017  Securus Technologies, ... technology solutions for public safety, investigation, corrections and ... Recidivism and Reentry. "Too often, too ... prisons and county jails are trying to tackle ... inmates and friends and family members. While significant steps ...
Breaking Biology News(10 mins):